BNP Paribas Financial Markets’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-432,535
| Closed | -$14.5M | – | 6137 |
|
|
2026
Q1 | $14.5M | Buy |
432,535
+219,717
| +103% | +$8.61M | 0.01% | 1358 |
|
|
2025
Q4 | $9.85M | Buy |
212,818
+204,710
| +2,525% | +$11.2M | ﹤0.01% | 1627 |
|
|
2025
Q3 | $548K | Buy |
8,108
+4,541
| +127% | +$337K | ﹤0.01% | 3495 |
|
|
2025
Q2 | $299K | Buy |
3,567
+2,331
| +189% | +$174K | ﹤0.01% | 3606 |
|
|
2025
Q1 | $88.3K | Sell |
1,236
-70,084
| -98% | -$3.41M | ﹤0.01% | 4081 |
|
|
2024
Q4 | $3.21M | Buy |
+71,320
| New | +$3.7M | ﹤0.01% | 2073 |
|
|
2022
Q4 | – | Sell |
-9,333
| Closed | -$15.6K | – | 4542 |
|
|
2022
Q3 | $15.6K | Sell |
9,333
-2
| -0% | -$5 | ﹤0.01% | 4131 |
|
|
2022
Q2 | $25.9K | Hold |
9,335
| – | – | ﹤0.01% | 3670 |
|
|
2022
Q1 | $31.2K | Sell |
9,335
-11
| -0.1% | -$57 | ﹤0.01% | 3653 |
|
|
2021
Q4 | $57.5K | Sell |
9,346
-10
| -0.1% | -$105 | ﹤0.01% | 3717 |
|
|
2021
Q3 | $130K | Buy |
9,356
+5
| +0.1% | +$70 | ﹤0.01% | 3188 |
|
|
2021
Q2 | $160K | Sell |
9,351
-544
| -5% | -$9.19K | ﹤0.01% | 2917 |
|
|
2021
Q1 | $187K | Sell |
9,895
-126
| -1% | -$4.06K | ﹤0.01% | 3072 |
|
|
2020
Q4 | $290K | Sell |
10,021
-170
| -2% | -$4.91K | ﹤0.01% | 2712 |
|
|
2020
Q3 | $384K | Buy |
10,191
+780
| +8% | +$22.8K | ﹤0.01% | 2376 |
|
|
2020
Q2 | $313K | Buy |
9,411
+83
| +0.9% | +$3.6K | ﹤0.01% | 2298 |
|
|
2020
Q1 | $333K | Buy |
+9,328
| New | +$397K | ﹤0.01% | 2581 |
|
BNP Paribas Financial Markets's SLNO Position: Q2 2026 in Review
BNP Paribas Financial Markets sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 432,535 shares — an estimated $14.5M sold.
BNP Paribas Financial Markets first reported a position in SLNO in Q1 2020 and held it in 17 quarters. The position peaked at $14.5M in Q1 2026. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- BNP Paribas Financial Markets reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- BNP Paribas Financial Markets sold 432,535 Soleno Therapeutics shares in Q2 2026, an estimated $14.5M.
- BNP Paribas Financial Markets first reported a position in Soleno Therapeutics in Q1 2020 and held it in 17 quarters.
- BNP Paribas Financial Markets's Soleno Therapeutics position peaked at $14.5M in Q1 2026.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.